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Following the banking cycle of umbilical cord blood in India: the disparity between pre-
banking persuasion and post-banking utilization 
 




To address critique of the rare uptake of umbilical cord blood (UCB) in private banks, 
hybrid-banking models would combine the advantages of ‘public UCB banking’ and private 
UCB banking by responding to both market forces and public needs. We question both by 
following the cycle of UCB banking in India: the circulation and stagnation of UCB as waste, 
gift, biological insurance, enclaved good, source of saving lives, and commodity through 
various practices of public, private and hybrid UCB banking. Making the journey from 
‘recruitment’, ‘collection’ and ‘banking’ to ‘research’ and ‘therapy’ allowed us to identify 
concerns about the transparency of this cycle. Drawing on archival research and fieldwork 
interviews with different stakeholders in UCB banks in India, this article shows how 
private/hybrid cord blood banks are competing for their market share and its implication for 
the circulation of UCB: speculation, stagnation and opacity. 
 







Umbilical cord banks store umbilical cord blood (UCB) for future use. Both private and 
public cord blood banks have been established to treat diseases of immunological systems 
and blood disorders, such as leukemia. The aim of a public UCB bank is to treat anyone 
whose treatment requires UCB, while private banks store blood for potential use by paying 
customers and their families. As explained below, controversy exists between those that 
support private and those that support public UCB banks:  the former claim that private banks 
are underused and store blood that would be more effectively and fairly used by public banks 
(see Hauskeller & Beltrame in this special issue); the latter argue that public banks are too 
expensive for small and developing countries, as private banks make use of higher numbers 
of stored blood units and can be cheaper compared to pubic banks, which tend to ask for high 
release fees (see Chang in this special issue). As is explained in this article, an evaluation of 
the degree of public-spiritedness and efficacy of different forms of UCB banking requires us 
to move beyond a simple taxonomy, and requires an overview of the process of UCB banking 
as a whole, the socio-economic context in which it occurs, and insight into the attitudes that 
are being cultivated among the public towards risk and science. Our contribution is to take an 
initial step towards such evaluation. 
 The last few decades have witnessed the emergence of newly globalized tissue 
economies (Waldby and Mitchell 2006) with innovative life science and medical 
biotechnology industries established around the sourcing and circulation (Brown et al. 2011) 
of human tissues. The transformation of UCB from a waste by-product to a source of stem 
cell interventions, ranging from leukemia to sickle cell disease, has given rise to a globalized 
commercial sector in cord blood banking, a sector based largely on promises of future 
therapies (Santoro 2009; Brown 2013). In 2013, there were over 500 UCB banks worldwide 
(Sharma 2013), and in India, in 2015, five out of fourteen UCB banks claimed to have 
“public” cord blood facilities (hybrid banks), the remainder being private (Parents Guide 
2015).1   
 Private stem cell banks were established in India prior to any systematic public stem 
cell banking initiative in other countries, the high expenses involved of which were 
unaffordable to India. Private banks rapidly spread throughout the country, but the contesting 
claims about their sample size, recruitment strategies, banking methods, and transplantation 
possibilities renders clear insight into India’s UCB banking scene impossible. Reliance Life 
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Sciences (RLS) established the first public cord blood bank in 2002, followed by Relicord, 
Cryo Stemcell, Jeevan, and StemCyte. Although they collectively have over 60,000 units, as 
we shall see, their public banks are mainly extended programs of their private, main banks 
and are extremely small. Relicord and StemCyte are the two leading private stem cell banks 
that have both private and public banking facilities. Jeevan Bank is a not-for-profit 
community blood bank located in Chennai, and provides both private and public UCB 
banking facilities to its clients and donors (Jeevan Bank 2014). Other private banks include 
LifeCell, CryoBank, CryoSave, Cord Life, Baby Cell, Stem One, ISCSL and TranScell 
Biologics. Apart from some hospital-based repositories made for small-scale research studies 
and applications and the All India Institute of Medical Sciences (AIIMS) in New Delhi 
(Agarwal 2006; McKenna and Sheth 2011), there are no public UCB banks established, 
funded, or promoted by the state. With over 150,000 cord blood units in 2013, the private 
stem cell banking industry in India was valued at Rs. 200 crore (US$32m) and estimated to 
reach Rs. 2700 crore (US$430m) by 2020, accounting for 17% of the world market 
(Pharmabiz 2013).  
 With India’s booming birth rate of 27 million births per year (Pharmabiz 2013), the 
country is poised to be the largest collector of UCB in the world (McKenna and Sheth 2011). 
UCB banking is an expanding biotech sector in India, where leading enterprises are 
competing with each other to capture the market. The ‘hyping’ tactics (Brown and Kraft 
2006; Sunder Rajan 2006) of these enterprises promise cures through the application of new 
biomedical technologies. Such promises are accompanied by a general trend of 
responsibilization of the population (Rose 2007), whereby populations are made aware of the 
“risk” associated with giving birth to a child with inherited and late-onset diseases, and are 
encouraged to take responsibility to address those risks (Beck 1992; Alaszewski 2003; Gupta 
2010; Sleeboom-Faulkner 2010). Citing statistics from the science literature to point out the 
disease risks for children at birth and presenting parents-to-be with UCB as “biological 
security" has led to the normalization of commercial UCB storage among the middle classes, 
transforming the valuation of umbilical cords as waste (Hodges 2013) to a precious and life-
saving resource.   
 But private UCB banking has been at the core of international controversy, which 
pitches solidaristic donation – making UCB publicly available for use - against private 
storage, whereby estimations of the odds that a person will need their own (autologous) UCB 
ranges from 1 in 10,000 to 1: 250,000 (Rosenthal 2011). Private banking has been criticized 
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for threatening the supply of cord blood to the public system, and causing a stagnation in the 
circulation of potentially life-saving UCB. Furthermore, it has been accused of displacing 
proven therapeutic uses of cord blood in the public sector with uses whose benefits are 
largely speculative (O’Connor et al 2012: 513). It has been argued that hybrid models of 
public and private UCB banking are a viable alternative for countries that cannot afford to 
run a public UCB bank. Hybrid banks would provide both private and public storage options 
(O’Connor et al 2012; Chang 2014) and facilitate a higher uptake of UCB units compared to 
public banks. This is because they can both respond to market demand and fulfill the needs of 
the community (O’Connor et al 2012; Brown et al 2011; Chang 2014). Even though hybrid 
banking can, in principle, resolve some of the problems associated with UCB banking, in this 
article we identify some major challenges. First, the responsibilization of families that 
normalizes UCB banking requires that families can make an informed decision as to whether 
and where to bank UCB. This in turn requires that families have full insight into the process 
of UCB banking and a realistic idea of the medical application of UCB to realize the 
‘biological security’ promised. We argue that this is not the case. Second, the critique of 
private banking is not resolved by hybrid banking. The UCB stock in private banks is 
released back into circulation, but diverted in ways that are unclear and questionable.  
 
Following the life cycle of UCB banking 
In India, the creation of private and hybrid cord blood banking has been an obvious choice, 
considering the unavailability of funding for public UCB banks. But it is difficult to find 
balanced information about private and hybrid UCB banks in India: although data about 
recruitment, collection and payment are readily available in documentation provided by 
bankers, information about the handling and uptake of banked units cannot be found on 
websites and are often unclear when provided by UCB bank managers. As statistics on the 
collection and use of UCB blood are unreliable, and as it is beyond our ability to investigate 
UCB stored in all UCB companies in India, it was impossible for us to gain insight into a 
core question: Can potential clients of UCB banks in India make informed decisions about 
UCB storage regarding the cost, uptake and the use of UCB? To find out, we opted to follow 
the life cycle of UCB banks from recruitment, collection and banking to its utilization in 
research and medical interventions, surmising that it might give us insight into the process of 
UCB banking as an interconnected whole. The triangulation of information from parents, 
bank managers, technicians, sales people and scientists, we hoped, would enable us to 
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identify discrepancies between the quantity and quality of information provided to potential 
clients and the fate of the stored UCB units in the banking process.  
 We capture these weak links in reference to Appadurai’s work on the social life of 
things (1986), whereby some objects are exchanged through barter, the market and gifts, 
while others are taken out of circulation by being discarded as ‘waste’ or enclaved as ‘relics’. 
Similar to Appadurai, we treat demand (consumption) as an aspect of the overall political 
economy of societies: a function of a variety of social practices and classification, rather than 
a mysterious emanation of human needs, a mechanical response to social manipulation or the 
desire for available objects. We thus show how the upsurge in UCB banking is not so much a 
result of the need of the Indian population for stem cell therapy (Tiwari and Raman 2014) or 
a response to social manipulation (Bharadwaj and Glasner 2009; Patra and Sleeboom-
Faulkner 2013), but part of the health-industry boom driven by the promissory bioeconomy 
and the introduction of biomedical risk categories into society (Sunder Rajan 2006).   
 We suggest that, in theoretical terms, although private UCB banking belongs to the 
‘luxury register’ of consumption (Appadurai 1986: 38) among the middle- and higher income 
classes, what is consumed is the suggested sense of safety sold with the storage. In the 
process, the banking causes stagnation by diverting objects from circulation --  enclavement 
in Appadurai’s terms, while at the same time earning profit through the storage of the 
enclaved blood. The use of the notion of ‘enclavement’ here differs from that of Appadurai: 
although consumption of UCB is contractually reserved, the customer pays for the object to 
be kept out of circulation. Thus, although UCB sets off a financial flow, the minimalisation of 
its physical consumption here means maximal efficacy. Thus, unlike religious relics, which 
are enclaved for their sacred value, and unlike “money in banks”, which invest capital, in 
private UCB banking UCB units are largely stocked as a commerical solution to hyped risk 
and for high payments. For this solution to be relevant and for high payments to materialise, 
however, companies invest in groundwork to the effect that parents learn about the 
vulnerability of children to diseases, and persuading them that UCB storage renders optimal 
security. In this sense, storage results from an ideology that enclaves UCB blood as a form of 
perceived security. The cases in which UCB units are dispensed, this happens in ways 
unclearly related to medical interventions and experimental research, and for this reason 
remains hidden. This has the effect that little is known among clients about the use of UCB 
blood other than for therapy.  We argue that it is the potential use of the UCB units that 
clients pay for, and that transparency around its dispensation is crucial.  
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Method 
This article is based on data gathered through both primary and secondary sources. It draws 
on research that explores the institutional, socio-economic and managerial aspects of UCB 
banking entrepreneurship in India, conducted over five months, between August and 
December 2013. During this period, we explored the lifecycle of UCB banking from 
recruitment, collection and banking to research and therapy. Gaining an overall view, we 
intended to shed light on the conditions under which UCB circulates between different 
spheres (private, public, state, science, health) and in various guises (waste, gift, good, 
insurance, source, etc.), which we hoped would provide us with insight into the entire cycle. 
With this aim in mind, we collected data about UCB banks of various size and origin, and 
with various aims. 
 We have visited multiple sites across India that include five stem cell banks, four stem 
cell companies, five stem cell research institutes, and four clinics where we interviewed 
donors/clients (four), sales executives (five), gynecologists (three), stem cell researchers 
(eleven), scientists (seven), therapy providers (six), bioethicists (five), venture capitalists 
(one) and patients/caregivers (eight). The institutes/centers/stem cell banks and hospitals 
visited include the Stempeutics Research Pvt. Ltd., International Stemcell Services Limited 
(ISSL) and Manipal Institute of Regenerative Medicine in Bangalore, Jeevan Stem Cell Bank, 
Lifeline Institute of Regenerative Medicine (LIRM) and Nichi-In Centre for Regenerative 
Medicine (NCRM) in Chennai, StemCyte in Ahmedabad, ReeLabs and NeuroGen in 
Mumbai, Chaitanya Stem Cell Centre and LifeCell in Pune, CryoBank in Gurgaon, Indian 
Institute of Medical Science & Research, Udaan Centre and AIIMS, TranScell Biologics Ltd. 
in Hyderabad, and Kalinga Institute of Industrial Technology (KIIT) in Bhubaneswar. 
Secondary source materials such as webpages of the above institutes/centers, newspaper 
articles, and conference materials are referenced. We have anonymised the names of 
interviewees by using pseudonyms. Although CEOs of companies were happy to be 
mentioned by name, we still preferred to use pseudonyms for all individual interviewed, as 
our aim is to clarify the lifecycle of UCB, rather than to attract attention to individual 
persons.  
 Although UCB banks use different methods and have multiple purposes in practice, 
we initially aimed to follow the lifecycle of UCB processing as commonly advertised by 
UCB banks: recruitment, banking, and utilization. Doing this helped us realize that important 
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parts of the life cycle of UCB banking, methods of transportation, monopolization and the use 
of UCB in research are underexposed and transplantation is overexposed. Subsequently, we 
added “transportation” and “research using UCB” to the lifecycle. It also helped us compare 
statements of people involved in different parts of the lifecycle of UCB banking, which in 
this article comprises recruitment, transportation/collection, UCB banking, transplantation 
and research. As we will show, UCB banking as a life-saving tool or biological security is 
rarely materialized; in private banks, it usually stagnates as stock, and to the extent that UCB 
is mobilized, it is diverted into biomedical pathways that have remained unclear to us. The 
relevance of the notions of stagnation/circulation in the context of the life cycle of UCB units 
is that these concepts force us to focus on the issue of application: whether it sits in a bank as 
stock, or whether it returns to circulation. Following the life cycle of UCB can yield socio-
economic and ethical insights into the UCB banking cycle (recruitment, collection, storage, 
life saving therapy). Thus, a view of the entire life cycle of UCB banking helps us address 
two issues: Whether prospective parents have sufficient information before deciding whether 
to store UCB, and whether the hybrid model of UCB banking can help solve the problems 
associated with private UCB banking, as explained above.  
 
The lifecycle of UCB banking 
 
In this part we follow the lifecycle of UCB banking, comprised of recruitment, collection and 
transportation of UCB, banking, research and transplantation (see figure).  
 
 





This section shows the groundwork done to facilitate recruitment and marketing among 
prospective parents to persuade them of the privilege of storing UCB privately. This 
groundwork entails persuading prospective parents of the high risk of inherited disease in 
India, the safety and security of UCB banking, the use of additional insurance, and its 
affordability.  
 In India, UCB was previously discarded as medical “waste,” but has increasingly 
become a source for stem cell transplantation and research. This increase in value has 
required substantial groundwork. As sales executive, Mr Reddy, of LifeCell narrated: 
 
Some four to five years back we really had to work hard to convince the expectant 
parents, and even obstetricians and other health-care providers, about the regenerative 
benefits of UCB. It was a worthless thing to them. But now, thanks to developments in 
science and increasing awareness among people, they value it  (Mr. Reddy, Sales 
Executive-4, Pune, dated 24-Oct-2013). 
 
A father who has stored his child’s UCB and tissue in one of the big private banks said: 
 
 I never imagined that something like a flesh tube or a cord that connect the mother with 
the child can have so much medical potential. I have stored it, but I am still amazed 
about its possibilities. It used to be buried under the soil so that animals cannot eat it. 
That would bring ill health for the child. It was nothing but garbage. But now, the same 
waste can be used to treat diseases; it is magic. Only science can do it  (Mr. Daar, father, 
39 years, interviewed in Hyderabad, on 24-Oct-2013). 
 
The costs associated with storing UCB, however, are high considering the low chance of its 
use, especially in the case of private banking. The uptake of the units by clients and the 
internationally acknowledged success of transplantation are rare. Nevertheless, private banks 
market their services to parents and health-care providers as a leading-edge medical 
technology (Sullivan 2008). 
 The decision of parents to bank the UCB of their child with a private banking 
company is primarily based on ‘facts’ presented to them by experts employed by banking 
companies, including references to articles about consanguineous marriage, the numbers of 
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infants born with chromosomal and genetic disorders, and malformation. Expert views and 
the presentation of such “facts,” coupled with a trend of parent preference for a limited 
number of children in rapidly growing urban middleclass society, have raised people’s 
concern about their future health status and biological destiny. As one mother, who has 
stored her child’s UCB with TranScell Biologics, a Hyderabad-based private CB bank, 
says: 
 
Every day you hear about a new disease. Sometimes they are scary; you always think 
that might happen to my child. Money is nothing before that helplessness. So, that 
made us to think of this banking  (Interview, Mrs. Komra, Aged 38 years, Mother of 
four, dated 28-Oct-2013, Hyderabad).  
 
Private UCB banks target specific populations that are “at risk.” According to Mr Rohan, a 
sales representative of a large bank operating throughout India, these include “the rich, 
upper-middle-class, small-sized, nuclear-family-oriented couples in urban India, high-
salaried IT professionals, parents belonging to ethnic and religious groups that practice 
consanguineous marriage, people with family history of members with some kind of 
genetic disorder” (Rakesh, Bhubaneshwar, 12-Nov-2013). As one pregnant mother said 
when asked why she was planning to bank the umbilical cord of her child: 
 
 In my aunt-in-law’s family there is a 12-year-old girl with thalassemia. I have seen 
how they struggle to arrange for blood transfusions. I am sure that we do not need to 
worry, as both I and my husband have been tested. But, you never know: some disease 
might express in a later stage. Since both I and my husband are working, we cannot 
afford to have more than one child. We came to know about UCB banking through 
our gynecologist. It is an once-in-a-lifetime chance, so we have decided to bank the 
umbilical cord of the child. We have already registered with LifeCell  (Interview, 
Mrs. Gupta, expectant mother, 31 years, Bhubaneswar, 16-Nov-2013). 
 
Expert knowledge has normalized new risk cultures that can be hedged by banking. The 
UCB banking industry further creates concerns about banking security and safety measures in 
the race to acquire customers. Thus, the company LifeCell provides dual-storage facilities at 
Chennai in south India and Gurgaon in north India as a security measure against natural 
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calamity in one of the locations. Mr Ravi, a sales executive of LifeCell, believes it improves 
the scope for recruitment: 
 
 Dual-storage facilities make the sample secured. You never know: something like a 
tsunami that affected the Chennai coast a few years back, or an earthquake like that 
happened in Gujarat. Though our facilities are earthquake proof. It is better to divide 
your sample and keep it at two places, to be on the safe side  (Interview, Sales 
Executive-3, Chennai, 14-Octo-2013). 
 
Some clients are influenced by the good infrastructure of a bank’s facilities, but others feel 
that accreditation by competent national and international agencies is more important. Still 
others feel contact with the sales executive or regional manager is crucial, and there are those 
who bank if a friend or relative has previously stored cord blood in a bank. As a couple 
working as IT professionals in a multinational company, Mr. and Mrs. Manohar have decided 
to store their child’s UCB with a private bank:  
 
 What we did is, we checked their website. They have the necessary ISO certificates, the 
facilities are absolutely shielded and equipped to handle calamities of any sort. The 
buildings are earthquake proof, the cylinders for cell storage are waterproof and can 
withstand any kind of calamity including tsunami (Mr. and Mrs. Manohar, interview of 
parents in LifeCell, 2014). 
 
Cord blood banks such as StemCyte and LifeCell display their licenses, registrations and 
accreditations wherever possible, including ISO, American Association of Blood Banks 
(AABB), the National Accreditation Board for Testing and Calibration Laboratories (NABL), 
and the Drug Controller General of India (DCGI). Interviewed customers generally show 
awareness of accreditation. 
 At a private bank, the UCB unit belongs to the client: a family storing a unit with a 
private bank is said to have a degree of “biological insurance.” Banks are also providing life 
insurance coverage to their clients through private-sector insurance companies. For example, 
LifeCell has an arrangement with Max New York Life Insurance (MNYL). But most 




 For me there are three main reasons why I decided to bank with LifeCell. First, they are 
India’s largest stem cell bank, second would be they store samples in two places that is 
safe. The third reason is that they provide a 10 lakh rupees insurance promising to 
arrange stem cells from other banks in case they fail. So, that is reducing my burden in 
future and ensuring the future health of my child. That I appreciate  (Mrs. and Mr. 
Gandi, interview available in LifeCell webpage 2014). 
 
The arrangement between cord blood banks and life insurance companies is designed to 
influence the decision-making of clients in the recruitment process. 
 Even though UCB banking is still viewed as elitist (Hodges 2013), novel methods to 
make it affordable through innovative payment methods enabled the expansion of private 
banks, such as LifeCell and CryoBank, to small cities and towns in India. The recent 
announcement by the Union government of India in February 2014 to withdraw the 12.36% 
service tax on cord blood banking will create financial leeway for promoting the concept of 
“’biological insurance’ among the middle classes” (The Telegraph 2014; IMT 2014). The 
CEO of LifeCell, the largest Indian cord blood bank with over 80,000 customers, said:  
 
We understand the importance of educating expectant parents on the value of UCB 
banking and our effort is to offer an affordable UCB banking to reach out to maximum 
number of families … (Pharmabiz, 8-Oct-2013). 
 
LifeCell has several payment plans towards the storage fee. It charges Rs. 19,900 
(approximately US$350) as an enrolment and cord blood and tissue processing-fee. Then it 
charges Rs. 4,000 (approximately US$70) as an annual storage fee. There are options for 
storing cord blood at single or dual-storage facilities with different fee structures. Similar 
attempts to slash the stem cell processing and storage fees have been made by other banks, 
such as StemCyte and CryoBank. TranScell, a small-scale private bank based in Hyderabad, 
charges a one-time Rs. 75,000-100,000 for collection, processing, and storage for 21 years.  
 This section has tried to illustrate how prospective parents are educated as to how 
UCB banking can abet the Indian population’s major risk of developing disease by 
commercially enclaving UCB in biobanks. Considering the rapid increase of UCB banking 
and support by the state, companies have succeeded in normalizing the practice, but it is also 





Collection and Transportation 
Commercial cord blood banking is characterized by strong competition, involving the ability 
to deal with complex logistics, large connection networks with hospitals covering 
increasingly large areas, and the flexibility and speed needed to collect and transport the UCB 
to banks. 
 Private UCB companies generally collect UCB at the birth hospital and ship it to the 
private bank. The collection takes place after and before the delivery of the placenta. To date, 
little data is available to suggest which of the two collection methods is safest and which 
allows for the optimal collection of UCB (Smith and Thomson 2000). However, our research 
has noted frequent complaints regarding the inexperienced nature of the collecting go-
betweens and mediating company representatives. Collection involves complex networks 
where stakeholders such as doctors, nurses, and other health-care providers, sales executives 
of the UCB bank, the pregnant mother, expectant parents, and family closely interact. In the 
process clients are compelled to use the hospitals that collaborate with the UCB banks they 
have a contract with.  
 Some banking companies have arrangements with doctors and obstetricians, whom 
they appoint to panels, which link the banks with a range of hospitals. Such “syndicate of 
doctors” is paid by the bank to allocate prospective patients to the hospitals they have deals 
with. To maximize the number of clients, a bank needs to have links with a large number of 
fertility clinics, hospitals, obstetricians, and midwives to bring prospective parents into 
contact with the sales executive appointed to a particular area. In this exercise, larger banks 
are in an advantageous position compared to smaller banks, such as TranScell. As the CEO of 
LifeCell said: 
 
We have tie-ups [agreements] with 300 hospitals at 110 locations. So any mother 
delivering in these hospitals can donate her umbilical cord to us … There are no hurdles 
as far as the hospitals and doctors are concerned (Mr. Chandramauli, CEO, LifeCell, 
Pharmabiz, 12-Nov-2013). 
 
The companies that have large hospital networks have an advantage over others. As the CEO 




LifeCell or StemCyte have more money, trained executives, and wider network with 
hospitals and clinics. They give better salaries to their executives, and better perks to 
doctors and people who help them with recruitment of clients. In my company, sales 
executives leave after about four-to-six months. I am unable to pay competitive 
incentives to our panel doctors. So, that affects your business (Interview, Dr. S. Kumar, 
CEO-1, TranScell, in Bhubaneswar, 14-Nov-2013). 
  
Apart from wide networks, robust infrastructural facilities, and funding to incentivize 
syndicate agents, the speed and safety of collection are crucial to both clients and bankers. 
Thus, TranScell provides its services mainly to clients living in the city of Hyderabad, where 
the company is based. Many prospective parents and pregnant mothers visit the TranScell lab 
and storage facility center, where scientists and trained staff reassure them that their sample is 
stored in a timely manner and in a safe place. Most banks have one, or at best two, 
centralized storage facilities, but their collection centers are spread throughout the country or 
concentrated in the area of operation. Banks advertise the robustness of their logistics and the 
efficacy of their collection and transport ability. LifeCell has partnered with Sequel Logistics, 
a logistics company, to offer “Personalized Shipment Service.” Efficacious collection and 
transport are projected as something that would enhance the quality and viability of the stem 
cells.  
 This section showed the importance of UCB networks to the growth and survival of 
the enterprise. In this competitive arena, the smaller banks with limited networks, such as 
TranScell and International Stem Cell Services Limited (ISCSL), find it difficult to compete. 
This has implications for the number of clinics they can reach and the number of samples 
they can collect. As we shall see, it also affects the way UCB banking companies diversify.  
 
UCB banking 
This point of the cycle was complicated: the banking itself, which is part of the cycle of UCB 
banking, can only be understood in terms of the kind of banking concerned. The diversity of 
UCB banking we came across make us realize that without clear information on the kinds of 
activity involved of UCB banks, potential donors cannot make appropriate decisions about 
donation. We have tried to depict the great variety of UCB banking in India in terms of the 
taxonomy below. The taxonomy is only of heuristic value, and serves to show the difficulties 
involved in potential parents’ decision-making around UCB banking. The taxonomy, 
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comprising public (not-for-profit) cord blood banks, local banks, global banks, charitable 
banks and academic/research banks, shows that UCB banking is far more complex than the 
simple division between private, public and hybrid banking would suggest.   
 
Public (not-for-profit) cord blood banks may collect and use the donated cord blood (gift to 
the public) for transplantation into a suitable match (e.g., unrelated allogeneic 
transplantation), while private banks collect and store the units for potential use by the 
newborn infant (autologous transplantation). In case of hybrid banking, the private bank adds 
a public part, which is financially supported by the private part; in the case of family banking, 
which can be an option in a private bank, a family member in need of a stem cell transplant 
procedure can also use the stored units. Depending on the kind of contract, the UCB can be 
collected and used for laboratory-based research studies and in clinical trials as well. The 
separation between these various activities, we will show, is unclear, largely due to the 
increased entwinement between competition and collaboration, and therapy and research. In 
this section, we classify UCB banks in India according to size, institutional embedding, 
collaborative network, service provision, and research. As will become clear, some banks are 
maintained as part of other activities organized around clinical stem cell applications and 
research.  
 Local banks have limited scope and their area of operation is restricted to a city or 
province. For instance, TranScell Biologics Private Ltd., a private UCB bank, stem cell 
service and research center based in Hyderabad, was initiated in 2008 by a scientist-cum-
entrepreneur. The scope of operation of this bank is limited to the city of Hyderabad and 
surrounding areas in the state of Andhra Pradesh in south India. Because of its limited 
infrastructural facilities and resources (small numbers of sales executives, health counselors, 
gynecologists in the service panel, logistical support for transportation of collected samples 
from distant areas, and lack of adequate storage facilities and research staff), the bank 
struggles to expand. As it aspires to become a national-level bank, it tries to create 
partnerships with private venture capital companies. The bank has about 4,100 UCB units 
stored at its facility, including 4,000 UCB units in private and 100 units in its public storage 
modes. Only five units of UCB have been used for stem cell transplantation purposes (both 
autologous and allogeneic) within India and abroad (the Middle East) (Interview Kumar, 14 
November 2013). To increase its revenue, TranScell has combined banking facilities with 




 Ours is a different kind of company that focuses on UCB banking, stem cell processing 
facilities and research on stem cell science. We have around 4,000 units under private or 
family banking, which is for the purpose of generating revenue. We charge around Rs. 
75,000 to 100,000 (US$1,300–1,700) per unit towards a one-time preservation fee for 
21 years. We also have around 100 units of UCB collected from voluntary donors that 
will be used for research purposes  (Interview, Dr. S. Kumar, CEO-1, TranScell, in 
Bhubaneswar, 14-Nov-2013).  
 
Local banks consider the expansion of collaborations with therapeutic or transplantation 
services as the logical next step towards increasing the scope of the enterprise. The same 
CEO explained company strategy:  
 
 My focus now is to increase the storage capacity, to explore collaborating 
opportunities, negotiate with investment communities, and to emphasize end-
user collaboration  (Interview, Dr. S. Kumar, CEO-1, TranScell, Bhubaneswar, 
14-Nov-2013). 
 
For this stem cell scientist, UCB banking served multiple purposes, including the financing of 
research, the provision of research materials and participation in clinical applications.  
 Global banks start either with support from a multinational company or as a branch of 
a foreign UCB bank with national presence, as in the case of LifeCell and StemCyte. LifeCell 
was launched in 2005 with technology licensed from Cryo-Cell USA. It is spread over more 
than 100 medical centers in India and, in 2014 it has over 80,000 UCB units preserved at its 
dual-storage facilities at Chennai in south India and Gurgaon in north India. The use of cord 
blood units from this largest UCB bank in India is, however, low: in 2013, LifeCell had 
released only 23 cord blood units for therapy out of an inventory of 70,000 units (Krishnan 
2013). 
 StemCyte India Therapeutics Pvt. Ltd., established in 2008, is a joint venture between 
StemCyte Inc. (USA), Apollo Hospital Enterprises Ltd., and Cadila Pharmaceuticals Ltd. 
StemCyte India’s headquarters are located in Ahmedabad, with the processing and storage 
facility at Apollo Hospital Campus in Gandhinagar, both in the state of Gujarat. StemCyte 
engages in the collection, processing, testing, and storage of both private and public UCB 
units and their therapeutic applications. The bank claims to have dual-banking facilities 
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(private and public) in India and more than 35,000 “racially diverse” UCB units in its public 
repositories in all its centers (StemCyte 2015). Its main objective is to build an inventory of 
“racially diverse” (Indian) UCB units. StemCyte’s CEO argues that there is less chance of 
immune rejection if cells of the same “race” are used (Hiddleston 2011), and the scarcity of 
some “racial units” is one of the most lucrative forms of UCB banking (Brown et al. 2011). It 
has a wide network of hospitals and contacts established all over India. StemCyte has 
provided more than 1,850 UCB units to over 200 transplant centers across six continents 
worldwide, and it has provided 27 cord blood transplants in India for hematopoietic diseases.  
 “Total” or “holistic” banks claim to provide “complete” stem cell services covering 
cell collection, processing, storage, and therapy provision. Examples are ReeLabs, Mumbai, 
and ISCSL, Bangalore. ReeLab was formed in 2009 as a stem cell therapy center, and it later 
added stem cell banking facilities for UCB, tissue, menstrual blood, and dental pulp. It also 
provides storage facilities to smaller companies that wish to store their samples for a fee. 
ReeLab claims to have 2,000 UCB units stored at its facility that has a 10,000 UCB storage 
capacity, and is planning to expand (Sudhendranath 2013). ReeLabs introduces itself as “a 
one-stop shop in stem cell medicine” with products such as “ReeCord for stem cell banking 
and ReeCure for stem cell treatments for various congenital, developmental, degenerative, 
and malignant disorders.” ISSL, in Bangalore, provides “complete” stem cell services, such 
as stem cell expansion, differentiation, cord blood banking, and treatments for diseases such 
as peripheral vascular disease, Buerger’s disease, osteoarthritis, diabetes, and renal failure. 
ISSL provides stem cell banking for UCB and tissues, and is engaged in stem cell research 
and therapy provisions.  
 A charitable bank is run by either a charitable trust or small private bodies, where 
amassing profit is not the major drive. Jeevan Stem Cell Bank (JSCB) based in Chennai is 
one example. JSCB is a unit of Jeevan Blood Bank and Research Centre, and collects both 
private and public cord blood units. Its public cord blood bank was set up in 2008, and at 
present it has an inventory of 700 UCB units. The Tamil Nadu government announced a grant 
of rupees 9 crore (US$150,000) to Jeevan’s public UCB bank in April 2013 to help the bank 
host a collection of 3,000 cord blood donations (Kumar 2013). The objective of JSCB’s 
public cord blood bank is to make available umbilical cord derived stem cells to patients in 
India, either free of charge for the poor or on a cost recovery basis for those who can afford 
it, and at a prescribed fee for those Indians living abroad. It also offers cord blood units to 
advance medical research. JSCB has also signed a memorandum of understanding (MoU) 
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with IIT (Indian Institute of Technology), Madras, in March 2013 for research and 
development in stem cell biology. 
 An academic or research bank is attached to or run by government-funded academic 
research institutions or hospitals. The primary aim is to promote basic research on stem cells 
with or without translating it into therapeutic application, which we discuss in the next 
section. 
 
Considering the variety of UCB banks, it should be clear that categorizing the UCB banks in 
India in terms of private/public/hybrid is unhelpful, as most banks are commercial hybrids. 
Of the banks discussed, only the charitable and academic/research banks are not-for-profit, 
even though all charge fees for the uptake of UCB. For the purpose of examining the 
circulation of UCB, the banks are better classified according to size, institutional embedding, 
collaborative network, kind of service provision, and research, as these tell us something 
about the advertised functions of the UCB.  
 
UCB transplantation 
This section discusses the sourcing of UCB units, and involves the disentanglement of 
commercially stored UCB units as transplants from private storage into clinical therapies. As 
therapies for diseases other than blood disorders are not recognized as evidence–based and 
require permission from the National Apex Committee (CDSCO 2013; Tiwari and Raman 
2014), many of the applications mentioned below are controversial. 
 Most UCB banks in India have been established in the last few years, and UCB 
transplantation is in its infancy (McKenna and Sheth 2011). Only one cord blood bank, 
StemCyte India, has published a detailed list of its UCB transplantations on its official 
website, claiming that it is the “only company having clinical experience of treating 52 
hematopoietic diseases and the record of providing more than 2,000 cord blood units for 
transplantation across 235 centres worldwide.” It further claims to have facilitated 27 cord 
blood transplants in India, for which it provides a list of 25 disease conditions, including 
thalassemia major (13), aplastic anemia (2), relapsed bilineage leukemia (1), spinal cord 
injury (2), AML (1), Hurler’s syndrome (1), CGD (1), infantile ALL (1), relapsed ALL (1), 
HLH (1) and Fanconi’s anemia (1) (StemCyte 2015). Some of these transplantations are 
experimental, so effectiveness is by no means guaranteed.  
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 McKenna and Sheth (2011) have reported that 32 patients in India have had 
transplantations using related or unrelated UCB, including 13 cases of thalassemia. Of these, 
six cases were transplanted using fully-matched sibling-UCB at Apollo Hospitals, Chennai. 
UCB units were obtained from LifeCell and CordBank. Similarly, seven unrelated UCB units 
were utilized to treat thalassemia cases at Gujarat Cancer & Research Institute (GCRI), 
Ahmedabad. The unrelated UCB units were procured from private UCB banks, namely 
Relicord and StemCyte. Hyderabad-based TranScell has provided its UCB units for five 
transplantations (both autologous and allogeneic) to centers in India and one in the Middle 
East (personal communication with CEO, TranScell, 14 November 2013). Furthermore, it 
advertises that stored UCB is used for therapeutic interventions for cancers, blood based 
disorders, brain and neurological disorders, diabetic ulcers, eye/ocular disorders, muscular 
dystrophies, autoimmune diseases and bone and cartilage defects, most of which it also 
conducts experimental research on (Transcell 2016).  
 Some banks, such as ReeLab in Mumbai and ISCSL in Bangalore, have been 
established for the declared purpose of providing all necessary stem cell therapeutic services 
to patients requiring them. ReeLab’s CEO said: 
 
 ReeLab claims that it is the only firm that processes and stores stem cells from all 
possible sources and uses it for therapy. We’ve had cases where the stored samples have 
been retrieved and used for therapy of family members. Other market players are merely 
storing cord and cord blood stem cells. No other company is into stem cell therapy  
(Abhijit Bopardika, CEO, Dental Stem Cell Division, ReeLab) (Sudhendranath 2013). 
 
It has become clear from the examples above that applications of UCB units for both routine 
and controversial therapies are provided to patients. Interviewed patients said that they had 
not been made aware of the controversial nature of these therapies or the origin of the UCB. 
Nor did they realize that the advertised lists of disorders to which stem cells had been applied 
gave no information on whether they had been applied successfully. Discussion with patient 
groups for spinal cord injury and muscular dystrophy in India made clear that one of the most 
urgent demands is clarity around the scientific state-of-the-art of the therapies on offer 
(Workshop Bangalore, October 2013). Knowledge about the safety and efficacy of therapies 
has implications for the decisions made by expecting parents at the recruitment phase of the 




Research using UCB 
This section discusses the relationship between research using UCB and its sourcing, 
involving the disentanglement of commercially banked UCB units from stock into research 
projects in private and government institutions. For decision-making purposes, prospective 
parents should have information about what proportion of the UCB stock is diverted into 
research. Provided literature and customer agreements, however, does not make this clear. 
 Many private and public institutions and hospitals without adequate banking or 
cryopreservation facilities are involved in research activities using UCB, including StemCyte 
India, who operates a hybrid public and private bank “to store UCB stem cells and use them 
to prevent and treat various diseases and health disorders,” including spinal cord injury, HIV, 
cardiac repair and stroke (StemCyte 2015). Apollo Hospitals has a 51-49 partnership with 
StemCyte with an initial investment of US $15 million to carry out research on chronic 
strokes, spinal cord injury, and muscular dystrophy. A UCB bank is functional at Apollo 
Ahmedabad as a joint venture between Apollo Group, StemCyte Inc., and Cadila 
Pharmaceuticals (Anna University 2014).  
 TranScell Biologics Ltd. claims to have 4,000 UCB units under private banking 
facilities and around 100 UCB units under its public collection for research purposes. 
TranScell is also collaborating in international trials and allocating its resources for research 
purposes, by using its “good manufacturing practice” (GMP) stem cell processing units. One 
officer explained that the company has three stem cell products in its pipeline for the 
treatment of osteoarthritis, muscular dystrophy, and solid tumors (Interview, Dr. S. Dravida, 
CEO-1, TranScell, in Bhubaneswar, 14 November 2013). As stem cell treatment for these 
diseases is not evidence-based, and as the company has not had official permission for 
conducting clinical trials, questions of legitimacy and awareness arise.  
 Another leading private stem cell research institute is Nichi-In Centre for 
Regenerative Medicine (NCRM), an Indo-Japanese collaborative stem cell institute based in 
Chennai, which has entered into partnership with charity-based Jeevan Stem Cell Bank in 
Chennai. It manages both private and public banking facilities and reportedly has an 
inventory of 700 UCB units under its public banking facilities (Interview, Mrs. Sindh, 
Researcher at Jeevan Blood Bank, Chennai, 13 October 2014). Similar issues of the 
proportion used for research and the legitimacy of the research arise, with the extra 
complication of whether private or public UCB units are used.  
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 There are no data available on the amount of UCB collected and stored at any 
government-funded research institute or hospital in India. However, there are reports that 
suggest stem cell research using UCB is being carried out at several centers. For example, a 
joint study by Dhot et al. (2003) conducted at the Department of Transfusion Medicine, 
Armed Forces Medical College, Pune and Armed Forces Transfusion Centre at Army 
Hospital Research & Referral (AHRR), New Delhi, reported that 172 samples of UCB were 
collected and cryopreserved. The study aimed to improve techniques for the collection of 
cord blood, to study the influence of cryopreservation on stem cell count, and to carry out 
cord blood stem cell transplantation at AHRR in New Delhi. For this study, pregnant women 
undergoing full term vaginal deliveries at these centers were randomly selected at the time of 
admission for delivery, with informed consent (Dhot et al: 2003; Wadhwa et al. 2013). 
 AIIMS, the premier medical hospital and research center based in New Delhi, set up 
India’s first UCB bank in the government repository in 2006. It collects UCB from “the five 
to eight deliveries that happen daily in the institute” with parents’ consent, for “use in treating 
patients of cancer and other debilitating diseases” and, as of now, this is only for “in-house” 
patients, but the Institute has ambitious plans for setting up a national cord blood bank 
(Ghosh 2006). The Stem Cell Facility at AIIMS is currently undertaking a research project on 
the “isolation and expansion of mesenchymal stem cells (MSCs) from human bone 
marrow/umbilical cord and the evaluation of its cardiomyogenic and neurogenic 
differentiation potential,” for which it is using UCB units collected from donors that give 
birth there (Interview, PH-2, 30 Sept. 2013). Besides these centers, other government-funded 
public institutes and hospitals use UCB in their research, including the Cancer Research 
Institute of Tata Memorial Centre, Mumbai, and the National Centre for Cell Sciences 
(NCCS), Pune (cf. Wadhwa et al. 2013; Chandra et al. 2011).  
 
The origin and conditions for UCB units used for stem cell research in the cases above are 
mostly unclear. CEOs of the banks usually do not provide clear information about UCB 
pathways, which indicates that clients and donors are not informed about them. Some 
companies, such as StemCyte India, reassure their clients that:  
 
If StemCyte India fails to provide viable stem cells during retrieval, StemCyte will try 
to provide a matching sample from its international public inventory or would pay up 
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to 20 Lakh rupees, whichever is less, to the parents. (Varies according to plan chosen) 
(Stemcyte India 2016).  
 
Publications do not usually mention the source of UCB units used, let alone the 
circumstances and arrangements made for their use. Although much of the UCB derives from 





Making use of Appadurai’s work on the circulation of objects, we identified issues 
concerning the stagnation of UCB through UCB storage and the opaque way in which it is 
diverted into use. It became clear that informational disparity exists between information 
provided during the recruitment and collection phases of UCB banking and their utilization 
after. In other words, by following the life cycle of UCB banking, we found a disparity 
between pre-banking persuasion and post-banking utilization of UCB. We conclude that for 
patients to decided whether to bank UCB with private and hybrid UCB banking models in a 
more balanced manner, potential clients need more clarity about the proportions of UCB and 
the pathways along which they return to circulation. 
 The medical utility of privately banked UCB is of a potential rather than actual nature, 
and the uptake rate of UCB is low and its recognition for the purpose in regenerative 
medicine is limited. Due to the limited uptake of UCB by clients, then, cord blood either 
stagnates in private banks or is diverted into unclear pathways. In India, private UCB banking 
has thrived over the last decade, and the introduction of ‘hybrid’ models, which appeal to 
public values and have broadened the scope for UCB exchange, has added to its commercial 
success. Examining the life cycle of UCB banking allowed us to identify various issues 
related to UCB banking in India, including hybrid banking, summarized in Table 1. 
 We conclude that prospective clients of UCB banks do not receive balanced 
information about the benefits of banking UCB and its utilization. The introduction of 
discourses using unclear scientific jargon such as ‘risk’ has made potential parents sensitive 
to speculation about the possibility that their child would be born with genetic and other 
disorders. Pseudo-scientific information and disinformation about the use, storage and safety 
of application have been instrumental in persuading parents, anxious to provide security for 
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their potential offspring, to store UCB. In short, it is not made clear to clients what happens to 
the units after the contract ends and under what conditions the units can be used in clinical 
trials and in medical interventions, or sold as part of medical products, such as platelet gel 
and platelet rich plasma (Cryo Stemcell 2015). 
 Hybrid banking, due to support for the public part by the private part, has been 
portrayed as representing communitarian values (O’Connor et al 2012) and stimulating the 
cell flow and research collaboration (Chang 2014). Although in India hybrid banking has 
enabled the increase and diversity of uptake of UCB, in our study the client was not informed 
about the public proportion of UCB uptake and the utilization of samples. This is important, 
as the public part is usually small and the utilisation of the samples can vary from evidence-
based applications to save lives to experimental interventions and the creation of medical 
products. Furthermore, the free collection and storage of donated UCB is often 
counterbalanced by high release charges. As the ownership of the units lies with the bank, the 
clients are entirely dependent on the bank’s network linking UCB banking, research centers, 
and hospitals of both private and public origin, and its ability and knowhow regarding the 
uptake, matching and use of UCB. We also saw that the various banks have different 
strategies of dealing with samples. Smaller enterprises can only survive by combining 
banking with activities that divert UCB into the realm of experimental research applications. 
 On the basis of the observed data, we conclude that in many respects the 
nomenclature of UCB banking in terms of public/private/hybrid is misleading: a hybrid bank 
does not necessarily mean that the bank operates on communitarian principles or yields 
efficacious therapies for its costumers. An alternative taxonomy of UCB banking categorised 
in terms of size, institutional embedding, collaborative network, service provision, and 
research may be more useful to understand the commercial, public and collaborative 
activities of UCB banks. And as for prospective UCB-banking clients, as long as there is no 
transparency about the issues outlined above, the division of public/private and hybrid is 
misleading at worst and confusing at best. 
 
Table 1: Issues related to the life cycle of UCB banking 
Recruitment - Speculation on potential disorders of prospective child 
- Use of ‘scientific’ vocabulary to gain scientific authority 
- Withholding of information about the odds of UCB uptake 
- Use of misleading terms such as ‘biological security’ 
- Provision of one-sided information on safety storage 





- Clients were not told about controversies around the timing of UCB 
collection or the need to utilize only hospitals in the bank’s network 
- The speed of collection varies with the size of the network, as banks 
may be located at a distance, something that clients may not realize 
- The hype around ‘safety’ and ‘personalized’ services may draw 
attention away from other issues mentioned above 
UCB banking - No transparency about the uptake of UCB units, the quality of the units 
stored, the numbers used for research, therapy and other purposes 
Research - Little clarity about the proportion of banked UCB units 
used/sold/bartered for research and the creation of cell products 
- Clients are not made aware of research & commercial activities before 
signing contracts 
Transplantation - Conditions other than blood diseases require NAC-permission for 
treatment with UCB. They usually have no permission. Interviewed 
clients were generally not aware of this.    
- Clients are usually not aware of the (lack of) medical potential of UCB 




1  The banks we include here are Cordlife India, Babycell, Cryo Stemcell, Cryo-Save India, Cryo Banks India, 
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